Table II.
Observational longitudinal studies.
| Author, year (ref.) cancer type | Aim | Follow-up | Cohort Overall survival (OS) | Disease-free survival (DFS) | Hazard ratio (HR) |
|---|---|---|---|---|---|
| Lehnert et al, 2013 (11) Breast | Evaluation of HtrA1 mRNA expression on patient outcome Two groups selected with a cut-off of 48 |
60 months 120 months |
60 months: 85±3.2% SE 120 months: 66±4.9% SE |
60 months: 75±4.0% SE 120 months: 54.5±5.2% SE |
OS: HR 0.45 (95% CI 0.23–0.90) P=0.023 DFS: HR 0.55 (95% CI 0.32–0.94) P=0.028 Lymph node-positive groups: OS: HR 0.21 (95% CI 0.07–0.63) P=0.006 DFS: HR 0.29 (95% CI 0.13–0.65) P=0.003 |
| (see Table III for Laboratory techniques) | Therapy groups: (none, endocrine, chemotherapy) OS: HR 0.23 (95% CI 0.07–0.72) P=0.0012 DFS: HR 0.29 (95% CI 0.13–0.67) P=0.004 |
||||
| Xia et al, 2013 (45) Esophagus | Correlation between HtrA1 levels and survival | 60 months | The overall cohort survival, disease-free survival and HR: were not reported. Reported date included: HtrA1 mRNA-positive: 13 of 39 patients died (33.3%) HtrA1 mRNA-negative: 56 of 76 patients died (73.7%) (P<0.05) |
||
| Catalano et al, 2011 (12) Stomach | Determine HtrA1 expression as predictor of chemoresponse in patients with advanced gastric cancer Two groups high/medium expression vs. low expression (see Table III for laboratory techniques) | 60 months | 17.0 months: high/medium HtrA1 expression 9.5 months: low HtrA1 expression | Not reported, they evaluated time to progression High and medium HtrA1 expression compared with low: 0.52 (95% CI 0.29–0.93) P=0.027 | OS: HR 0.55 (95% CI 0.32–0.96) P=0.037 |
| Mullany et al, 2011 (46) | Dichotomized into 2 groups high intensiy score vs. low | 200 months | Not reported | No significant relationship between high-medium expression of HtrA1 and survival | |
| Endometrium Zhu et al, 2010 (10) Liver | Dichotomized into 2 groups high intensity score vs. low | 72 months | HtrA1 (+++/++) survival rate 46%, median survival 35.5 months HtrA1 (+) survival rate 26%, median survival 15.6 months Cohort OS, DFS and HR not reported |
||
| Baldi et al, 2008 (9) Pleural mesothelioma | Analyzed the potential prognostic value of expression of HtrA1 Three class of HtrA1 expression: low medium high | 40 months | HtrA1 (+): median survival time (months), 6.0 (95% CI 4.46–7.51) HtrA1 (++): median survival time (months), 16.0 (95% CI 12.54–19.45) HtrA1 (+++): median survival time (months), 24.0 (95% CI 20.50–27.49) P<0.0001 | Not reported | HtrA1 (+): HR 1 (reference category) HtrA1 (++): HR 0.65 (95% CI 0.348–0.876) HtrA1 (+++): HR 0.26 (95% CI 0.122–0.454) P<0.001 |